The recent phase 1/2 study of Pfizer-BioNTech’s combination vaccine candidate demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. This promising development could significantly impact global immunization practices.

The recent study underscores the readiness of pharmacists to dispense mifepristone following the FDA’s rule change. With basic training, nearly all participants expressed confidence in their ability to dispense this medication, highlighting your adaptability and resourcefulness.

As pharmacists, it’s crucial to note that, although these changes in FDA guidelines may not directly impact your practice, they signify a shift in how biosimilars will be identified moving forward. This could potentially influence how you advise patients about these products.

As we navigate the uncharted waters of Long COVID, pharmacists are emerging as key players in patient care. With your unique expertise in medication management and patient education, you’re helping patients manage a wide range of lingering symptoms and improve their quality of life.

The study’s findings underscore the importance of addressing the high cost of insulin. Despite new products and discounts entering the market, one in four patients still report cost as a barrier to accessing their necessary insulin.

As we navigate this new era of oncology care, it’s important to remember that only 38% of studies combining chemotherapy with a targeted treatment administered both drugs at full dose. This underscores the need for careful dose adjustments when combining different classes of drugs.